Demographics, risk factors, clinical history, and outcomes in tirofiban group
| Patients | Sex/age (y) | Risk factors | Evidence of AP by CTA | NE before treatment | Duration of the episode | Maximum NIHSSs | Fluctuation after tirofiban | NIHSS at 24 hours | mRS at 3 months | IL on MRI |
| Group I | ||||||||||
| 1 | M/80 | Hy, Dy, CS, CD | + | 3 | 5–10 min | 8 | − | 0 | 0 | / |
| 2 | F/64 | Hy, Dy | + | >7 | 30 min | 6 | − | 2 | 0 | PP-L |
| 3 | F/43 | Hy, Dy | + | 6 | 10–30 min | 11 | + | 0 | 0 | AChA-R |
| 4 | M/66 | Hy, Dy, CD | + | 6 | 60 min | 3 | − | 1 | 1 | PP-R |
| 5 | F/48 | Hy, Dy | + | >9 | 2–10 min | 14 | − | 0 | 0 | AChA-R |
| 6 | M/79 | CD | + | 3 | 20–40 min | 5 | − | 0 | 0 | AChA-L |
| 7 | M/82 | Hy, CS | + | 7 | 1–2 min | 8 | − | 0 | 0 | AChA-L |
| 8 | M/60 | CS, CD | + | 5 | 10–30 min | 8 | − | 0 | 0 | AChA-R |
| 9 | F/62 | Dy | + | >5 | 10–60 min | 10 | − | 0 | 0 | AChA-L |
| 10 | M/56 | Dy, CS, CD | + | 3 | 2–3 min | 5 | − | 0 | 0 | DWI (-) |
| 11 | M/51 | Dy, CD | + | 5 | 20 min | 4 | + | 0 | 0 | AChA-R |
| Group II | ||||||||||
| 12 | M/63 | Hy, Dy, CS, CD | + | 4 | 5–100 min | 11 | − | 0 | 0 | AChA-R |
| 13 | M/48 | Hy, Dy, CS, CD | + | 12 | 5–20 min | 12 | + | 2 | 1 | AChA-R |
| 14 | M/28 | CS, CD | - | 3 | 10 min | 3 | − | 0 | 0 | AChA-L |
| 15 | M/61 | Hy, Dy, CD | + | 4 | 10–60 min | 11 | + | 8 | 2 | AChA-R |
AChA-L, territory of left anterior choroidal artery; AChA-R, territory of right anterior choroidal artery; AP, atheromatous plaque; CD, current drinking; CS, current smoker; CTA, CT angiography; DM, diabetes mellitus; Dy, dyslipidaemia; DWI, diffusion-weighted imaging; Hy, hypertension; IL, infarct location; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; NE, number of episodes; PP-L, left paramedian pontine; PP-R, right paramedian pontine; /, not available; y, years of age.